Phase II Study of Pharmacokinetic Model-Based ATG Dosing to Improve Survival through Enhanced Immune Reconstitution in Pediatric and Adult Patients Undergoing Ex Vivo CD34-Selected Allogeneic HCT (PRAISE-IR)

加药 离体 药代动力学 医学 赞扬 免疫系统 药理学 体内 免疫学 心理学 生物 生物技术 心理治疗师
作者
Michael Scordo,Miguel‐Angel Perales,Audrey Mauguen,Andrew Lin,Binni Kunvarjee,Linh K. Nguyen,Jennifer Bieler,Maria Pena,Christina Cho,Boglarka Gyurkocza,Andrew C. Harris,Ann A. Jakubowski,Richard J. Lin,Esperanza B. Papadopoulos,Ioannis Politikos,Doris M. Ponce,Brian C. Shaffer,Gunjan L. Shah,Barbara Spitzer,Roni Tamari,Sergío Giralt,Jaap Jan Boelens,Kevin J. Curran
出处
期刊: [Elsevier BV]
卷期号:30 (2): S487-S487
标识
DOI:10.1016/j.jtct.2024.02.008
摘要

Ex vivo CD34-selected allo-HCT is associated with favorable CRFS but limited by delayed immune reconstitution (IR) and in some trials higher non-relapse mortality (NRM) (BMT CTN 1301, JCO 2023). We recently reported that the use of traditional weight-based ATG dosing in this setting led to high post-HCT ATG pharmacokinetic (PK) exposure that was associated with delayed CD4+ T cell IR (CD4+IR) and increased NRM risk (Lakkaraja et al., Blood Adv 2022). Between 5/2021-12/2023, we conducted an investigator-initiated, single-center, phase II study of population PK model-based ATG dosing targeting a low post-HCT exposure with the aim of improving CD4+IR (NCT04872595). Pediatric and adult patients with hematologic malignancies undergoing their 1st allo-HCT received model-based ATG to target a post-HCT exposure of <20 AU*d/mL beginning on day -12 followed by a myeloablative conditioning regimen (Table 1) and a PBSC ex vivo CD34-selected allograft (CliniMACS CD34 Reagent System [Miltenyi Biotec, Gladbach, GER]) from a HLA 7-8/8 matched donor. The primary endpoint was the proportion of patients who reached CD4+IR, defined as CD4+ T cell values >50/µL at 2 consecutive timepoints by day +100. The trial size of N=56 was based on an optimal Simon 2-stage design that had 90% power to detect a 20% increase from a historical rate of 32% to ≥52%, with 5% 1-sided α. Successful CD4+IR was required in ≥24 of 56 evaluable patients to reject the null hypothesis. We defined time-to-CD4+IR as the time from HCT to CD4+IR. For this endpoint, we censored patients without CD4+IR by day +100 and considered death before CD4+IR by day +100 a competing risk. Other endpoints included the incidences of NRM and relapse, and rates of relapse-free (RFS) and overall survival (OS). To date, data were available for 59 patients: 3 were not evaluable and 2 are still within the 100-day period, leaving 54 evaluable patients. Among evaluable patients, the median age was 55 (range, 4-70), 32 (59%) were male, most (N=30; 56%) were treated for AML, and most (N=42; 78%) received regimen B. Median estimated pre- and post-ATG exposures were 52 (35.3-73.8) and 9.9 (4.3-16.1) AU*d/mL, respectively (Table 1). The median follow-up was 17 months (1-28). A total of 37 patients reached CD4+IR by day +100. Cumulative incidence of CD4+IR was 69% (95% CI, 56-81%). The 2-year incidences of NRM and relapse were 9% (0-17%) and 13% (3-24%), respectively. The 2-year RFS and OS rates were 78% (66-91%) and 86% (76-97%), respectively (Figures 1A-D). The use of model-based ATG dosing to achieve optimal post-HCT exposure led to high rates of CD4+ IR, thereby exceeding our primary objective. These CD4+IR rates came with low NRM resulting in highly favorable survival, suggesting that the NRM rates for ex vivo CD34-selected allo-HCT observed in trials such as BMT CTN 1301 were driven by high ATG exposure and may be offset by model-based dosing.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
123发布了新的文献求助10
刚刚
深情安青的应助被豆豆采纳,获得10
刚刚
徐州完成签到,获得积分10
1秒前
1秒前
科研通AI65的应助被狂野傲珊采纳,获得10
1秒前
汉堡包的应助被单身的盼雁采纳,获得10
2秒前
2秒前
木羽发布了新的文献求助10
2秒前
2秒前
Lucas的应助被shn采纳,获得10
3秒前
4秒前
4秒前
大模型的应助被123采纳,获得10
5秒前
汉堡包的应助被rainy采纳,获得10
6秒前
虚幻中蓝发布了新的文献求助10
7秒前
Ykaor完成签到,获得积分10
7秒前
zclm发布了新的文献求助10
7秒前
锅巴完成签到,获得积分10
7秒前
7秒前
传奇3的应助被缺粥采纳,获得10
7秒前
自由的大白完成签到,获得积分10
8秒前
healer发布了新的文献求助10
8秒前
牧青发布了新的文献求助10
8秒前
8秒前
111发布了新的文献求助10
9秒前
lalala发布了新的文献求助10
9秒前
11秒前
11秒前
12秒前
12秒前
豆豆发布了新的文献求助10
14秒前
真实的珠完成签到,获得积分10
14秒前
椰丝完成签到,获得积分10
14秒前
linlin发布了新的文献求助10
14秒前
小马甲的应助被一团毛线采纳,获得10
15秒前
CX330发布了新的文献求助10
15秒前
16秒前
共享精神的应助被cjh采纳,获得10
17秒前
在水一方的应助被背后子骞采纳,获得10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191812
求助须知:如何正确求助?哪些是违规求助? 9578503
关于积分的说明 21859856
捐赠科研通 7791184
什么是DOI,文献DOI怎么找? 3436733
关于科研通互助平台的介绍 2560447
邀请新用户注册赠送积分活动 2483502